Device and method for detection and treatment of syncope

• US 5,919,210 A
• Filed: 04/10/1997
• Issued: 07/06/1999
• Est. Priority Date: 04/10/1997
• Status: Expired due to Fees

• Current Assignee: PH Target, LLC
• Original Assignee: Pharmatarget, Inc.
• Inventors: Lurie, Keith G., Buscemi, Paul J., Benditt, David, Obino, Stanislao F.
• Primary Examiner(s): Kamm, William E.
• Assistant Examiner(s): SCHAETZLE, KENNEDY
• Application Number:
  US08/831,608
• Time in Patent Office: 817 Days
• Field of Search: 607/3, 607/120, 607/25, 600/509, 600/513, 600/515, 600/516, 604/890.1, 604/891.1, 604/19
• US Class Current: 607/3
• CPC Class Codes: A61M 5/1723 using feedback of body parameters, e.g. blood-sugar, pressure measurement of body parameters A61B5/00
• CPC Class Codes: A61N 1/365 controlled by a physiological parameter, e.g. heart potential evoked response A61N1/371
• CPC Class Codes: A61N 1/36571 controlled by blood flow rate, e.g. blood velocity or cardiac output
• CPC Class Codes: A61N 1/36592 controlled by the heart rate variability

Abstract

The invention disclosed herein relates to an implantable medical device for detection and treatment of syncope comprising an algorithm for determining the presence of syncope based on physiological activity associated with the onset of a syncopal episode, and a means for infusion a drug. Drug infusion therapy may be used along or in combination with pacing. The physiological activities detected and used by the device are selected from the group including changes in heart rate, heart rate variability, QT interval, PR interval, pressure, blood flow, vagal nerve activity, temperature, pH, and AV conduction times, respiration rate, position, motion, and combinations thereof. Drugs which may be used with the invention include pharmaceutical compositions which are capable of both endocardial administration and treatment of syncope, such as compositions comprising beta-blockers.

Claims

1. An implantable device for detection and treatment of syncope comprising:

means for sensing physiological activity associated with the onset of syncope;

means for determining the onset of syncope; and

means for infusing a therapeutically effective amount of a pharmaceutical composition for treating syncope directly into the heart.

2. The implantable device of claim 1, wherein the sensed physiological activity associated with syncope is selected from the group consisting of heart rate, heart rate variability, QT interval, PR interval, pressure, blood flow, vagal nerve activity, temperature, pH, and Av conduction times, and combinations thereof.

3. The implantable device of claim 1, further comprising pacing means.

4. A method for detection and endocardial treatment of syncope in a patient in need of treatment thereof, comprising:

sensing physiological activity associated with the onset of syncope;

determining the presence of an onset of syncope; and

infusing a therapeutically effective amount of a pharmaceutical composition for treating syncope directly into the heart in response to said determination.

5. A method for treating syncope comprising the steps of:

determining the QT/R--R ratio of a patient'"'"'s heart beat;

comparing the determined QT/R--R ratio with a baseline value for the QT/R--R ratio; and

infusing a drug into the heart for treatment of syncope, if the determined value of the QT/R--R ratio is less than the baseline value.

6. A method in accordance with claim 5, wherein the baseline value is determined by an average of the QT/R--R ratio for the patient over at least about the previous 1 to 5 minutes prior to the determining of the current QT/R--R ratio.

7. A method for treating syncope, comprising the steps of:

making a first comparison of the current QT/R--R ratio value of a patient to a baseline value;

making a second comparison of the then current value of the patient'"'"'s QT/R--R ratio with the baseline value at least about 1 minute after the first comparison; and

infusing drugs to the heart if the then current values of the QT/R--R ratios for the first and second comparison are less than the baseline values.

8. A method in accordance with claim 7, wherein the baseline value is determined by an average of the QT/R--R ratio for the patient over at least about the previous 1 to 5 minutes prior to the determining of the current QT/R--R ratio.

9. The method in accordance with claim 7, comprising the further step of:

making a third comparison, about 3 to 60 seconds after the second comparison, between the current value of the QT/R--R ratio and the then current QT/R--R ratio measured during the second comparison; and

pacing the heart if the current value of the QT/R--R ratio at the time of the third comparison is less than the current value of the QT/R--R ratio at the time of the second comparison.

10. The method in accordance with claim 7, comprising the further step of:

making a third comparison, about 30 to 60 seconds after the second comparison, between the current value of the QT/R--R ratio and the then current QT/R--R ration measured during the second comparison; and

pacing the heart if the current value of the QT/R--R ratio at the time of the third comparison is less than the expected value based upon trend analysis comparing the first and second QT/R--R ratio measurements.